B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $85 from $96 and keeps a Buy rating on the shares. The company’s Q1 earnings release lacked material updates, the analyst tells investors in a research note. The firm updated Viking’s model post the quarter.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics: Strong Financials and Promising VK2735 Program Drive Buy Rating
- Viking Therapeutics Advances Clinical Pipeline in Q1 2025
- Promising Developments and Financial Stability Underpin Buy Rating for Viking Therapeutics
- Viking Therapeutics reports Q1 EPS (41c), consensus (31c)
- Viking Therapeutics options imply 8.5% move in share price post-earnings
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue